Tempest Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Tempest Therapeutics, Inc. (TPST) reported Revenue from Contract with Customer, Excluding Assessed Tax of $55.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2018-11-09
- Tempest Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2018-09-30 was $55.00K, a 1.79% decline year-over-year.
- Tempest Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2018-06-30 was $81.00K, a 3.57% decline year-over-year.
- Tempest Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2017-09-30 was $56.00K.
- Tempest Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2017-06-30 was $84.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month |
|---|---|---|---|
| 2018-09-30 | $55.00K 10-Q · filed 2018-11-09 | $136.00K derived: sum of 2 quarters · filed 2018-11-09 | $203.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $81.00K 10-Q · filed 2018-08-09 | $148.00K 10-Q · filed 2018-08-09 | |
| 2017-09-30 | $56.00K 10-Q · filed 2018-11-09 | $140.00K derived: sum of 2 quarters · filed 2018-11-09 | $204.00K 10-Q · filed 2018-11-09 |
| 2017-06-30 | $84.00K 10-Q · filed 2018-08-09 | $147.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |